Do you have a thoracic oncology study/trial idea and are you attending #BTOG24 ?

Here's your chance to pitch your idea to expert researchers, a statistician and a professional lay advocate in our very own Dragons' Den style workshop!

Apply here tinyurl.com/pr55f8wx

Excited to share the first presentation of the preliminary activity and safety results on NVL-655, new ALK TKI. Brief recap here. Efficacy in heavily pretreated ALK+ NSCLC. Thanks to AACR #Targets23 for the opportunity to present, to collaborators, patients ALK Positive #LCSM

Delighted to share PhD student Emily Alger's latest paper which:
(i) Explores analysis of patient-reported outcomes (PROs) in dose-finding oncology trials,
(ii) Uncovers methodological weaknesses, and
(iii) Offers recommendations for PRO analysis
tinyurl.com/ryy3m3p9

If everyone who has been grateful for the NHS over the past 75 years followed and retweeted we’d reach a million by midnight

Please take just two seconds to show you’re right behind NHS staff

📢 Come and join us on 12 Sep 2023 for our The Royal Marsden NHS Foundation Trust Senior Adult Oncology study day to learn how a multidisciplinary approach improves the care of older adults with cancer

The study day is endorsed by SIOG

➡️ Info & registration: tinyurl.com/2fvmdv7y

#gerionc

NEW: In the RAGNAR single-arm ph2 trial of erdafitinib in pts w/ adv solid tumours with FGFR alterations, an objective response was seen in 64 (30% [95% CI 24–36]) of 217 patients across 16 distinct tumour types (median FU 17·9 months [IQR 13·6–23·9]).

thelancet.com/journals/lanon…

Well done Anna Minchom and team.

Have a look at Anna Minchom's, Johann de Bono's, Udai Banerji's & Juanita Lopez's poster on the CONSENT trial to improve #patient understanding of early phase clinical trials: bit.ly/3ONq9SM #CRUKFunded #ASCO23 The Royal Marsden NHS Foundation Trust The ICR

Abstract 9126: Subcutaneous amivantamab in patients with advanced solid tumors: The PALOMA study by Anna Minchom. IRRs were reported in 16% without grade 3 or more. PK analysis confirmed that ami SC 1600 mg Q2W shows similar exposure to the IV dose (1050 mg Q2W). #ASCO23 #LCSM

Our brilliant The Royal Marsden NHS Foundation Trust The ICR Drug Development Unit Advanced Nurse Practitioner Mary van Zyl talking ECMC Network networking day on improving accessibility to phase I studies.

Today is #ClinicalTrialsDay !

The ICR/The Royal Marsden NHS Foundation Trust' Drug Development Unit runs around 50 phase I trials at any one time, including trials of ICR-discovered drugs, developed by clinical academics, as well as drugs being developed with industry partners.

Importantly, through mentoring and training, Professor Stan Kaye, has played a major role in the careers of many clinicians and scientists around the world working in #CancerResearch .🌍

Find out more about Stan's incredible contributions to #Oncology 👇

icr.ac.uk/news-archive/p…

Professor Stan Kaye walking down memory lane, sharing anecdotes and words of wisdom. A giant in the world of medical oncology retired yesterday. We will miss him but his legacy of trainees across the world will continue the fight against cancer...The ICR The Royal Marsden NHS Foundation Trust

Last chance for NCRI #Lung_Group working group leaders! Applications for Chair & Deputy Chair for each new working and study group close on Sunday!
See our newly-published strategy here and sign up to the network for further comms on membership
👉ow.ly/iIbN50NQ7nN

We've extended the deadline for NCRI #Lung_Group working group leaders.
Applications for Chair & Deputy Chair for each new working and study group close on 21 May!
See here for more info: ow.ly/iIbN50NQ7nN
#Lung_Group

From BTOG Trainee Representative to fully-fledged plenary presenter: Dr Adam Januszewski gives a beautifully clean and clear talk on controversies in NSCLC with driver mutations

#BTOG23

Today, the NCRI Lung Group published its strategic priorities for 2023-2026!

We are now inviting applications for Chair and Deputy Chair of each new time-limited working group and the permanent Mesothelioma/Thymoma study group.

More information 👉 ow.ly/MMbk50NyQfC

#ELCC23 visit our poster. Demographic characteristics of ~7000 lung ca patients treated at Guys cancer centre SouthEast London 2010-21. The proportion of never-smoker lung cancer steadily increased from 5.1% in 2010 to 13.6% in 2021 Guy's Cancer Charity, everybreath.org.uk

#proudPI

I remember seeing news footage of Nigel Farage’s Brexit march consisting of about 30 bellends and a whippet…

But no British news coverage of this incredible strike action from yesterday: